M Ferrarini
Overview
Explore the profile of M Ferrarini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
200
Citations
3189
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou J, Di Fulvio A, Beyer K, Ferrarini M, Pullia M, Donetti M, et al.
Phys Med Biol
. 2020 Mar;
65(15):155002.
PMID: 32197258
Carbon-ion beams are increasingly used in the clinical practice for external radiotherapy treatments of deep-seated tumors. At therapeutic energies, carbon ions yield significant secondary products, including neutrons, which may be...
2.
Barisione G, Fabbi M, Cutrona G, De Cecco L, Zupo S, Leitinger B, et al.
Blood Cancer J
. 2017 Jan;
6(1):e513.
PMID: 28060374
No abstract available.
3.
Cutrona G, Matis S, Colombo M, Massucco C, Baio G, Valdora F, et al.
Leukemia
. 2017 Jan;
31(9):1894-1904.
PMID: 28053325
Chronic lymphocytic leukemia (CLL) clones are characterized by loss of a critical region in 13q14.3, (del(13)(q14)) involving the microRNA (miRNA) cluster miR-15a and miR-16-1. We have investigated the effects of...
4.
Ronchetti D, Manzoni M, Agnelli L, Vinci C, Fabris S, Cutrona G, et al.
Blood Cancer J
. 2016 Sep;
6(9):e468.
PMID: 27611921
Long non-coding RNAs (lncRNAs) represent a novel class of functional RNA molecules with an important emerging role in cancer. To elucidate their potential pathogenetic role in chronic lymphocytic leukemia (CLL),...
5.
Ferrarini M, Cutrona G, Neri A, Morabito F
Leuk Suppl
. 2016 May;
1(Suppl 2):S29-30.
PMID: 27175240
Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease, as some patients progress rapidly toward the more advanced studies, whereas others survive for a long period without the need for...
6.
Gentile M, Shanafelt T, Cutrona G, Molica S, Tripepi G, Alvarez I, et al.
Leukemia
. 2015 Dec;
30(6):1440-3.
PMID: 26648537
No abstract available.
7.
Facoetti A, Vischioni B, Ciocca M, Ferrarini M, Furusawa Y, Mairani A, et al.
Radiat Prot Dosimetry
. 2015 Apr;
166(1-4):379-82.
PMID: 25877541
In this article, the in vivo study performed to evaluate the uniformity of biological doses within an hypothetical target volume and calculate the values of relative biological effectiveness (RBE) at...
8.
Berti A, Ferrarini M, Ferrero E, Dagna L
Clin Exp Rheumatol
. 2015 Mar;
33(2 Suppl 89):S-155-63.
PMID: 25738753
Erdheim-Chester disease (ECD) is a rare inflammatory disorder of unknown etiology, characterised by diffuse organ infiltration of CD68-positive, CD1a-negative, S100-low/negative foamy histiocytes. It is a non-Langerhans cell histiocytosis which invariably...
9.
Pistoia V, Cozzolino F, Ferrarini M
Immunol Today
. 2014 Oct;
6(10):287-8.
PMID: 25290771
No abstract available.
10.
Caresana M, Cassell C, Ferrarini M, Hohmann E, Manessi G, Mayer S, et al.
Rev Sci Instrum
. 2014 Jul;
85(6):065102.
PMID: 24985847
LUPIN-II is an upgraded version of LUPIN, a novel rem counter first developed in 2010 specifically conceived to work in pulsed neutron fields (PNFs). The new version introduces some modifications...